Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety and immunogenicity of three BG505 MD39.3 HIV trimer mRNA vaccines (with gp151 and CD4KO variants) in HIV-uninfected adu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BG505 MD39.3 HIV Trimer mRNA Vaccine
• BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccine
• BG505 MD39.3 gp151 HIV Trimer mRNA Vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-31